Patented 3D bioprinting technique coming to market
Jetbio, a new spinout company, will be targeting the groundbreaking technique at drug discovery, tissue engineering and regenerative medicine.
11 March 2024
A new spin-out from Newcastle University is bringing patented technology to the global 3D bioprinting market.
Jetbio has been formed to market a 3D printing technique called Reactive Jet Impingement (ReJI). It is a fast, flexible system for printing biomimetic cell filled gels.
The technique jets two gel precursors at one another. They mix in mid-air and then land on a substrate as a gel. Because the two precursors are still liquid as they are bio-printed, lower pressures are used in the process which increases the viability to carry cells.
The Jetbio team are promoting the technology for us in drug discovery, tissue engineering and regenerative medicine.
Jetbio Chief Executive Dennis Camilleri said “New investment in Jetbio will enable the company to design and scale-up its products for manufacture and global distribution. The company is also planning to engage in funded collaborative partnerships by applying its team’s considerable know-how in this field. This is an exciting time for Jetbio.”
Jetbio Chief Scientific Officer and Newcastle University Professor of Manufacturing Engineering, Kenny Dalgarno said: “The technology is covered by granted patents in Europe and the USA and is underpinned by more than five years of research at Newcastle University.
"We have demonstrated high performance bioprinting for a number of potential healthcare applications, including research funded by Versus Arthritis, the EPSRC,
and the EC. We are looking forward to seeing our research being commercialised in 2024."
Drug discovery to support arthritis treatment
According to statistics obtained by Versus Arthritis, 10 million people in the UK have Osteoarthritis (OA), an estimated 5.4 million people have knee OA, and an estimated 3.2 million people have hip OA.
Versus Arthritis’ Director of Research and Health Intelligence, Professor Lucy Donaldson, said: “Versus Arthritis is the biggest dedicated charitable investor of arthritis research in the UK, changing lives through research, campaigning and support. We are thrilled to see the research we have invested in scaled-up for such innovative approaches, enabling scientists to discover breakthrough treatments and speed up their development.
"People with arthritis need more effective, reliable, and personalised treatments to help manage their condition. We look forward to seeing how Jetbio’s work will help refine the drug discovery process and offer people with arthritis access to the treatment they deserve sooner, allowing them to live the life they choose.”
